Global InformationSirtex information
 | This article contains content that is written like an advertisement. (August 2021) |
 | |
| Company type | Private |
|---|---|
| Founded | 1997 |
| Headquarters | Woburn, MA |
| Products | SIR-Spheres yttrium-90 resin microspheres |
| Owner | China Grand Pharmaceutical and Healthcare Holdings Ltd./CDH Genetech, Ltd. |
Number of employees | 1000 |
| Website | www.sirtex.com |
Sirtex Medical Limited is a medical device company, providing radioactive treatment for inoperable liver cancer called SIR-Spheres microspheres.[1] Sirtex was established in 1997 in Australia and currently maintains offices and manufacturing facilities in the U.S., Australia, Germany, and Singapore. Following an acquisition by China Grand Pharmaceutical and CDH Genetech, Sirtex delisted from the Australian Securities Exchange (ASX:SRX) on Monday, September 24, 2018.
The company is currently headed by Kevin R. Smith, who was appointed as CEO on October 16, 2019.[2]
- ^ "SIR-Spheres Microspheres Featured at the 2008 Society of Nuclear Medicine Annual Meeting - Drugs.com MedNews". Drugs.com. Retrieved 29 July 2010.
- ^ "Press Release October 16, 2019: Sirtex Medical Appoints Kevin R. Smith as Chief Executive Officer".